Tools / Drug approvals and letters / Drugs Pravastatin Sodium Sold as Pravachol. Every FDA application for this active ingredient: 1 branded and 18 generic.
As of Nov 16, 2026, FDA lists 19 applications for Pravastatin Sodium (sold as Pravachol), first approved Oct 31, 1991, with 16 new uses approved and 0 published complete response letters.
First approved : Oct 31, 1991 Applications : 19 New uses approved : 16 Complete response letters : 0 Medicare spending, 2025 : $123M
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Where Medicare Prescribes It 9.4M Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate South Carolina 1.6×, Louisiana 1.4×, Mississippi 1.4×
Least Puerto Rico 0.4×, Colorado 0.7×, California 0.7× What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change PRAVASTATIN SODIUM 10 MG TAB: $0.057 per unit Generic · -11% in a year PRAVASTATIN SODIUM 20 MG TAB: $0.057 per unit Generic · -19% in a year PRAVASTATIN SODIUM 40 MG TAB: $0.079 per unit Generic · -12% in a year PRAVASTATIN SODIUM 80 MG TAB: $0.136 per unit Generic · -15% in a year FDA Drug Safety Communications One communication since 2020 that name this drug; see all communications Clinical Trials 16 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention Hyperlipidemia · Xin Li — Active, not recruiting Nov 16, 2026 A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Diabetic Kidney Disease (DKD), Type 2 Diabetes · Beijing University of Chinese Medicine Phase 2 Active, not recruiting Oct 30, 2026 Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma Melanoma · University of Colorado, Denver Not applicable Recruiting Jul 15, 2026 Novel Treatment of Radiation Associated Dysphagia With Statins Radiation-associated Dysphagia, Head &Amp; Neck Cancer · Peter MacCallum Cancer Centre, Australia Phase 2 Recruiting Oct 20, 2025 Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) Preeclampsia (PE), Intrauterine Growth Restriction (IUGR) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Phase 2 Recruiting Aug 1, 2025 Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) Fibrosis Syndrome, Lymphedema · M.D. Anderson Cancer Center Phase 2 Recruiting Apr 6, 2025 Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial Cardiovascular Diseases (CVD), Drug Effect · Tor Biering-Sørensen Phase 4 Not yet recruiting Mar 4, 2025 StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial Ischemic Stroke, Transient Ischemic Attack · Prof. dr. Nathalie van der Velde Phase 4 Not yet recruiting Jan 21, 2025
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Oct 31, 1991 Pravachol NDA 19898 · New molecular entity Bristol Myers Squibb56 Discontinued Apr 24, 2006 Pravastatin Sodium ANDA 76056 Aurobindo Pharma USA12 Marketed Oct 23, 2006 Pravastatin Sodium ANDA 76341 Apotex8 Marketed Oct 23, 2006 Pravastatin Sodium ANDA 76714 Dr Reddys Labs Inc7 Marketed Oct 23, 2006 Pravastatin Sodium ANDA 76939 Watson Labs7 Marketed Oct 23, 2006 Pravastatin Sodium ANDA 77013 Pharmobedient6 Discontinued May 11, 2007 Pravastatin Sodium ANDA 77987 Glenmark Pharms Ltd9 Marketed Jan 8, 2008 Pravastatin Sodium ANDA 77917 Chartwell Rx7 Marketed Jan 15, 2008 Pravastatin Sodium ANDA 77793 Aurobindo Pharma USA9 Marketed Feb 11, 2008 Pravastatin Sodium ANDA 77491 Pharmazone6 Marketed Apr 30, 2008 Pravastatin Sodium ANDA 77751 Zydus Pharms USA6 Marketed May 27, 2010 Pravastatin Sodium ANDA 79187 Pharmobedient6 Discontinued Mar 22, 2016 Pravastatin Sodium ANDA 77904 Cipla2 Marketed Nov 17, 2016 Pravastatin Sodium ANDA 207068 Accord Hlthcare4 Marketed Feb 2, 2017 Pravastatin Sodium ANDA 203367 Aurobindo Pharma3 Marketed Apr 13, 2018 Pravastatin Sodium ANDA 209869 Biocon Pharma3 Marketed Nov 23, 2018 Pravastatin Sodium ANDA 206061 Hisun Pharm Hangzhou0 Discontinued — Pravastatin Sodium ANDA 76445 Ranbaxy Labs Ltd0 Discontinued — Pravastatin Sodium ANDA 77730 Pliva Hrvatska Doo0 Discontinued
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA